Share

July 2021; 8 (4) ArticleOpen Access

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis

Claudia Sestito, Cyra E. Leurs, Martijn D. Steenwijk, John J.P. Brevé, Jos W.R. Twisk, Micha M.M. Wilhelmus, Benjamin Drukarch, Charlotte E. Teunissen, Anne-Marie van Dam, Joep Killestein
First published April 27, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000998
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
406

Share

Article Information

vol. 8 no. 4 e998
DOI: 
https://doi.org/10.1212/NXI.0000000000000998
PubMed: 
33906937
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 24, 2020
  • Accepted in final form February 22, 2021
  • First Published April 27, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Claudia Sestito, PhD (c.sestito{at}amsterdamumc.nl),
    2. Cyra E. Leurs, MD, PhD* (c.leurs{at}vumc.nl),
    3. Martijn D. Steenwijk, PhD* (m.steenwijk{at}amsterdamumc.nl),
    4. John J.P. Brevé, BASc,
    5. Jos W.R. Twisk, PhD (jwr.twisk{at}amsterdamumc.nl),
    6. Micha M.M. Wilhelmus, PhD (m.wilhelmus{at}amsterdamumc.nl),
    7. Benjamin Drukarch, MD, PhD (b.drukarch{at}amsterdamumc.nl),
    8. Charlotte E. Teunissen, PhD (c.teunissen{at}amsterdamumc.nl),
    9. Anne-Marie van Dam, PhD† and
    10. Joep Killestein, MD, PhD† (j.killestein{at}amsterdamumc.nl)
  1. Claudia Sestito, PhD (c.sestito{at}amsterdamumc.nl),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Cyra E. Leurs, MD, PhD* (c.leurs{at}vumc.nl),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Stichting MS Research (GRANT Number: 14-538e)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Martijn D. Steenwijk, PhD* (m.steenwijk{at}amsterdamumc.nl),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. John J.P. Brevé, BASc,
  5. Jos W.R. Twisk, PhD (jwr.twisk{at}amsterdamumc.nl),
  6. Micha M.M. Wilhelmus, PhD (m.wilhelmus{at}amsterdamumc.nl),
  7. Benjamin Drukarch, MD, PhD (b.drukarch{at}amsterdamumc.nl),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Charlotte E. Teunissen, PhD (c.teunissen{at}amsterdamumc.nl),
    9. Scientific Advisory Boards:

    1. Roche.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Roche, payment to my institute.

    Editorial Boards:

    1. CCLM special issue editor (2018-2019). Alz Res Ther Associate Editor (since 2020).

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. ZonMW, JPND

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Weston Brain Institute, Alzheimer Nederland, International Alzheimer Association.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Anne-Marie van Dam, PhD† and
    10. Scientific Advisory Boards:

    1. non-profit entity: Dutch MS Research Foundation

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neuropharmacology, editorial board member, 9 years Brain, Behavour and Immunity, editorial board member, 6 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Joep Killestein, MD, PhD† (j.killestein{at}amsterdamumc.nl)
    11. Scientific Advisory Boards:

    1. Steering committees Roche and Biogen trials

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria Biogen, Novartis, TEVA, Merck, Roche

    Editorial Boards:

    1. Editor of the official scientific journal of the Dutch Society of Neurology, the Dutch Society of Neurosurgeons and the Society of Flemish Neurologists (Tijdschrift voor Neurologie en Neurochirurgie). Editorial board MS Journal Editorial board Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have been involved in clinical trials of several companies that market drugs for MS. The past two years Biogen and Roche sponsored trials.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Amsterdam UMC, Vrije Universiteit, Amsterdam Neuroscience, MS Center Amsterdam, Department of Anatomy and Neurosciences (C.S., M.D.S., J.J.P.B., M.M.M.W., B.D., A.-M.v.D.), Department of Neurology (C.E.L., J.K.), Department of Epidemiology and Biostatistics (J.W.R.T.), and Department of Clinical Chemistry (C.E.T.), Amsterdam, the Netherlands.
  1. Correspondence
    Dr. van Dam amw.vandam{at}amsterdamumc.nl
View Full Text

Article usage

Article usage: April 2021 to April 2022

AbstractFullPdfSource
Apr 20214016245Highwire
May 20219488113Highwire
Jun 20211630925Highwire
Jul 20211014849Highwire
Aug 202176316Highwire
Sep 2021104216Highwire
Oct 202166433Highwire
Nov 202144938Highwire
Dec 202184722Highwire
Jan 20226608Highwire
Feb 202282614Highwire
Mar 202235416Highwire
Apr 202272511Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement